$VIR entry PT 42-44 Long term Target PT 200
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $200
CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants
KEY POINTS:
- Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmithKline “stands up well” to all variants.
- The companies announced contracts to sell $1 billion worth of sotrovimab to the U.S. government. The FDA has already granted sotrovimab an emergency use authorization to treat mild to moderate Covid infections.
- Though Scangos said the delta variant is “going to be with us for a while,” he added that sotrovimab could likely protect against new variants that emerge.
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants
KEY POINTS:
- Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmithKline “stands up well” to all variants.
- The companies announced contracts to sell $1 billion worth of sotrovimab to the U.S. government. The FDA has already granted sotrovimab an emergency use authorization to treat mild to moderate Covid infections.
- Though Scangos said the delta variant is “going to be with us for a while,” he added that sotrovimab could likely protect against new variants that emerge.
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.